| Literature DB >> 29261124 |
Yoshiaki Manse1, Kiyofumi Ninomiya2,3, Ryosuke Nishi4, Yoshinori Hashimoto5, Saowanee Chaipech6,7, Osamu Muraoka8,9, Toshio Morikawa10,11.
Abstract
In our continuing study of biologically active natural products from the fruit of Alpinia galanga (Zingiberaceae), we newly isolated three new labdane-type diterpenes, termed galangalditerpenes A-C (1-3), along with four known sesquiterpenes (4-7) and two diterpenes (8 and 9). The stereostructures of 1-3 were elucidated on the basis of their spectroscopic properties. The melanogenesis inhibitory activities in theophylline-stimulated murine B16 melanoma 4A5 cells of these isolates, including the new diterpenes (1-3, IC50 = 4.4, 8.6, and 4.6 μM, respectively), were found to be more than 6-87-fold higher than that of arbutin (174 μM), a commercially available positive control.Entities:
Keywords: Alpinia galanga; galangaldeterpene; labdane-type diterpene; melanogenesis inhibitor
Mesh:
Substances:
Year: 2017 PMID: 29261124 PMCID: PMC6149739 DOI: 10.3390/molecules22122279
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of isolates (1–9) from the fruit of A. galanga.
NMR data (800 MHz, CDCl3) for galangalditerpenes A–C (1–3).
| Position | 1 | 2 | 3 | |||
|---|---|---|---|---|---|---|
| δH ( | δC | δH ( | δC | δH ( | δC | |
| 1 | 1.04 (ddd, 3.2, 12.8, 12.8, Hα), 1.87 (ddd, 2.4, 3.2, 12.8, Hβ) | 39.4 | 1.02 (ddd, 4.0, 12.8, 12.8, Hα), | 39.0 | 0.96 (ddd, 3.6, 12.8, 12.8, Hα), 1.42 (m, Hβ) | 40.5 |
| 2 | 1.60 (m, Hα), 1.51 (ddddd, 2.4, 3.2, 12.8, 13.6, 14.4, Hβ) | 18.6 | 1.76 (ddddd, 2.4, 3.2, 4.0, 4.0, 14.4, Hα), 1.50 (ddddd, 3.6, 4.0, 12.8, 13.4, 14.4, Hβ) | 18.5 | 1.51 (m, Hα), 1.41 (m, Hβ) | 18.3 |
| 3 | 1.19 (ddd, 4.0, 13.6, 13.6, Hα), 1.41 (ddd, 2.4, 2.4, 13.6, Hβ) | 41.6 | 1.20 (ddd, 4.0, 13.4, 13.4, Hα), | 41.8 | 1.17 (ddd, 3.2, 13.6, 13.6, Hα), 1.43 (m, Hβ) | 41.9 |
| 4 | 33.4 | 33.3 | 33.5 | |||
| 5 | 0.96 (dd, 2.4, 12.8) | 55.5 | 0.96 (dd, 2.4, 12.4) | 54.5 | 1.00 (dd, 2.4, 12.0) | 54.2 |
| 6 | 1.74 (dddd, 2.4, 4.4, 4.4, 13.6, Hα), 1.15 (dddd, 2.4, 3.2, 12.8, 13.6, Hβ) | 20.5 | 1.74 (m, Hα), 1.35 (dddd, 4.0, 12.0, 12.4, 12.4, Hβ) | 20.0 | 1.71 (br ddd, ca. 2, 6, 14, Hα), 1.66 (dddd, 4.0, 12.0, 13.6, 14.4, Hβ) | 19.9 |
| 7 | 1.64 (m, Hα), 1.84 (ddd, 2.4, 3.2, 12.8, Hβ) | 40.1 | 1.40 (dddd, 4.0, 12.0, 12.4, 12.4, Hα), 1.74 (m, Hβ) | 26.8 | 1.97 (ddd, 5.6, 13.6, 14.4, Hα), 1.42 (m, Hβ) | 18.3 |
| 8 | 84.7 | 2.28 (dddd, 3.2, 5.6, 12.0, 14.4) | 53.8 | 58.2 | ||
| 9 | 1.64 (m) | 57.4 | 1.54 (ddd, 3.2, 6.4, 14.4) | 50.3 | 1.42 (br d, ca. 10) | 56.9 |
| 10 | 39.5 | 37.5 | 39.5 | |||
| 11 | 2.40 (br dd, ca. 9, 13, Hα), 2.57 (ddd, 8.8, 10.4, 12.8, Hβ) | 24.7 | 1.81 (ddd, 6.4, 9.6, 12.8), | 29.9 | 6.49 (dd, 10.4, 16.8) | 144.4 |
| 12 | 6.87 (ddd, 2.4, 8.8, 8.8) | 157.6 | 6.62 (dd, 6.4, 9.6) | 139.6 | 6.01 (d, 16.8) | 135.8 |
| 13 | 140.4 | 126.2 | 198.4 | |||
| 14 | 2.27 (ddd, 2.4, 3.2, 16.0, Hα), 3.13 (dd, 5.6, 16.0, Hβ) | 29.6 | 2.70 (m), 2.74 (m) | 25.3 | ||
| 15 | 5.44 (dd, 3.2, 5.6) | 100.4 | 4.34 (ddd, 6.4, 7.2, 14.4), | 65.4 | ||
| 16 | 9.35 (s) | 194.1 | 171.1 | 2.23 (3H, s) | 26.4 | |
| 17 | 3.62 (d, 9.6, Hα), 4.35 (d, 9.6, Hβ) | 70.4 | 9.28 (d, 5.6) | 203.8 | 2.31 (d, 4.8, Hα), 2.38 (d, 4.8, Hβ) | 48.8 |
| 18 | 0.80 (3H, s) | 21.5 | 0.84 (3H, s) | 21.7 | 0.90 (3H, s) | 21.9 |
| 19 | 0.89 (3H, s) | 33.5 | 0.89 (3H, s) | 33.4 | 0.91 (3H, s) | 33.5 |
| 20 | 0.81 (3H, s) | 14.9 | 0.87 (3H, s) | 14.2 | 1.09 (3H, s) | 15.6 |
Figure 21H–1H COSY, HMBC, and NOESY correlations of 1–3.
Figure 3Hypothetical pathway to galangalditerpene A (1).
Scheme 1Reagent and condition: (a) BF3·Et2O/toluene, 0–10 °C, 30 min, 23%.
Scheme 2Reagent and condition: (a) H2, 5% Pd/C(en)/THF, r.t., 6 h, 90%.
Inhibitory effects of the isolates (1–9) from the fruit of A. galanga on theophylline-stimulated melanogenesis and viability in B16 4A5 cells.
| Treatment | Inhibition (%) | IC50 (µM) | ||||
|---|---|---|---|---|---|---|
| 0 µM | 3 µM | 10 µM | 30 µM | 100 µM | ||
| Galangalditerpene A ( | 0.0 ± 4.6 | 48.3 ± 4.1 ** | 56.6 ± 6.9 ** | 67.9 ± 5.9 ** | 86.2 ± 4.4 ** | 4.4 |
| Galangalditerpene B ( | 0.0 ± 9.3 | 30.5 ± 9.1 ** | 50.9 ± 3.4 ** | 80.6 ± 2.3 ** | 85.3 ± 2.6 ** | 8.6 |
| Galangalditerpene C ( | 0.0 ± 9.5 | 40.6 ± 2.8 ** | 67.1 ± 2.2 ** | 82.5 ± 4.4 ** | — | 4.6 |
| Clovane-2 | 0.0 ± 3.4 | 23.9 ± 3.9 ** | 37.2 ± 2.6 ** | 64.0 ± 4.7 ** | 73.6 ± 3.7 ** | 17.7 |
| Caryolane-1,9 | 0.0 ± 6.0 | 37.3 ± 3.2 ** | 53.8 ± 2.0 ** | 52.7 ± 7.3 ** | 87.9 ± 3.5 ** | 9.4 |
| (−)-2-Oxoisodauc-5-en-12-al ( | 0.0 ± 11.8 | 45.9 ± 7.8 ** | 67.8 ± 3.3 ** | 85.1 ± 2.2 ** | 86.7 ± 4.0 ** | 2.9 |
| Kobusone ( | 0.0 ± 6.6 | −16.1 ± 3.6 | 20.5 ± 8.3 * | 51.5 ± 7.5 ** | 82.8 ± 2.7 ** | 29.8 |
| Galanolactone ( | 0.0 ± 9.4 | 38.6 ± 4.1 ** | 64.4 ± 7.5 ** | 83.8 ± 3.0 ** | — | 5.2 |
| ( | 0.0 ± 5.8 | 56.8 ± 3.4 ** | 60.8 ± 2.2 ** | 71.1 ± 1.4 ** | — | 2.0 |
| Arbutin [ | 0.0 ± 1.4 | 20.4 ± 0.5 | 38.1 ± 0.9 ** | 61.5 ± 0.6 ** | 83.7 ± 0.5 ** | 174 |
Each value represents the mean ± S.E.M. (n = 4); asterisks denote significant differences from the control group, * p < 0.05, ** p < 0.01; # cytotoxic effects were observed, and values in parentheses indicate cell viability (%) in MTT assay; commercial arubutin was purchased from Nakalai Tesque Inc., (Kyoto, Japan).